BNET Industries
Last Fiscal Year Sales:$10.0B
- Public
- JP
Dow Jones Description
Takeda promises better living through chemicals. Founded in 1781 and headquartered in Osaka, Japan, Takeda Pharmaceutical Company Limited is Japan's largest drug maker. The company, besides making pharmaceutical products, also offers vitamins, food additives, and some chemicals. It is developing drugs for a range of diseases and conditions. The company has annual revenues of about $10.4 billion and employs about 14,500 people. It recently announced plans to acquire Syrrx in order to start an R&D operation in the US.
Chairman & CEO
Kunio TakedaNumber of Employees 15,717
Peer Companies
NAICS Code Frozen Fruit, Juice, and Vegetable Manufacturing: 311411
Recent Events
-
Domain Therapeutics announces successful completion of the first milestone in its Research Agreement with Takeda...
-
Japan co Takeda Pharma licenses US co Amylin for obesity drug
-
Market Report -- In Play AMLN
-
Pharmaceuticals see proposed health care legislation as mixed bag
-
Takeda Pharma H1 Profit Soars; Updates FY09 Forecast - Update
-
Strong Yen Hits Drug Firms
-
Week of Oct. 12, 2009: GSK and Prosensa Form Pact; Cardiokine Appoints CEO; More...
-
Takeda San Francisco Enters Into A Sponsored Research Agreement With University of California, San Francisco...
-
Sepracor vows to stay in Mass.
-
Dainippon Agrees to Buy Sepracor
-
Takeda to start key diabetes drug trial in Sept
-
Alnylam Q2 net loss widens
-
UPDATE 1-Japan's Takeda to buy IDM Pharma in cancer drug push
News & Analysis
Filter by
takeda pharmaceutical company ltd. - All News and Analysis
AMITIZA® 8 mcg Now Available to Treat Irritable Bowel Syndrome with Constipation in Adult Women
- 2008-05-27
AMITIZA 8 mcg dose is the only widely available FDA-approved prescription medication for Irritable Bowel Syndrome with Constipation BETHESDA, Md. & DEERFIELD, Ill. -- Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) and Takeda Pharmaceuticals North America, Inc. today announced that AMITIZA([R]) lubiprostone 8 mcg capsules are now available by prescription in...
AMITIZA(R) (lubiprostone) 8 mcg Now Available to Treat Irritable Bowel Syndrome With Constipation in Adult Women
- 2008-05-27
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) and Takeda Pharmaceuticals North America, Inc. today announced that AMITIZA® lubiprostone 8 mcg capsules are now available by prescription in pharmacies across the U.S. for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in women 18 years and older. AMITIZA 24 mcg capsules...
Affymax® Reports Year End 2007 Financial Results
- 2008-03-13
PALO ALTO, Calif. -- Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the year ended December 31, 2007. The net loss for the year 2007 was $43.1 million compared to a net loss of $48.3 million for the year ended December 31, 2006. Affymax recognized revenue for the year...
Affymax Affirms Progress with Takeda Collaboration
- 2008-02-05
PALO ALTO, Calif. -- Affymax, Inc. (Nasdaq:AFFY) today affirmed its ongoing collaboration with Takeda Pharmaceutical Company Limited for the global development and commercialization of Hematide[TM], Affymax's lead product candidate for the treatment of anemia, continues to progress as planned. "Our partnership is unrelated to Takeda's recently announced agreement with...
New Study Demonstrates Ramelteon Does Not Exacerbate Respiratory Depressant Effects in Patients With Moderate-to-Severe COPD
- 2007-12-03
A new study presented today showed that ramelteon did not exacerbate respiratory depressant effects in patients (40 years and older) with moderate to severe chronic obstructive pulmonary disease COPD, as measured by oxygenation or abnormal breathing events relative to placebo. Results of this double-blind, placebo-controlled trial were presented at...
MEDIA ADVISORY: Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL With ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
- 2007-11-06
What and When Additional results from the clinical trial, CHICAGO (Carotid intima-media tHICkness in Atherosclerosis using pioGlitazOne), will be presented as an oral session at the American Heart Association Scientific Sessions 2007 being held November 4 through 7, 2007 in Orlando, Florida. Results revealed that reduced progression of...
"Move to AMITIZA" Advertising Campaign Underscores the Power of Not Letting Chronic Constipation Slow People Down
- 2007-11-06
Takeda Pharmaceuticals North America, Inc. and Sucampo Pharmaceuticals, Inc. today announced the launch of the first direct-to-consumer DTC advertising campaign for AMITIZA® lubiprostone, the only commercially available prescription treatment for Chronic Idiopathic Constipation in adults. The "Move to AMITIZA" campaign illustrates that the predictable relief (defined as 57%-63% had...
ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients With Type 2 Diabetes
- 2007-09-19
Results presented today at the 43rd Annual Meeting of the European Association for the Study of Diabetes demonstrate the ability of ACTOS® pioglitazone HCl to reduce the risk of ischemic cardiovascular disease in patients with type 2 diabetes. ACTOS is an oral antidiabetic agent for type 2 diabetes belonging...
Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD).
- 2007-09-13
BETHESDA, Maryland, September 13 /PRNewswire/ -- - First Patient Enrolled in Pivotal Studies Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) and Takeda Pharmaceuticals North America, Inc. today announced that the first patient has been enrolled in a Phase III study of lubiprostone (24 mcg,...
Danish pharmaceutical company H Lundbeck A/S signs cooperation agreement with Japan's Takeda Pharmaceutical Company Limited
- 2007-09-05
NORDIC BUSINESS REPORT-5 September 2007-Danish pharmaceutical company H Lundbeck A/S signs cooperation agreement with Japan's Takeda Pharmaceutical Company LimitedC1994-2007 M2 COMMUNICATIONS LTD http://www.m2.com Danish pharmaceutical company H Lundbeck A/S announced on Wednesday (5 September) a strategic alliance with Japan's Takeda Pharmaceutical Company Limited. The companies will cooperate in...
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Alan Mackenzie | President |
| Hiroshi Ohtsuki | President, Consumer Healthcare |
| Yasuchika Hasegawa | President & COO |
| Hiroshi Akimoto | Managing Director |
| Hiroshi Shinha | General Manager, Legal Dept |
| Hiroshi Takahara | General Manager, Finance & Accounting Dept |
| Kazuaki Ikeya | General Manager, Strategic Product Planning |
| Kiyoshi Kitazawa | General Manager, Pharmaceutical Development Division |
| Makoto Yamaoka | Managing Director & General Manager, Pharmaceutical Marketing Division |
| Naohisa Takeda | General Manager, Europe & Asia |
| Toyoji Yoshida | General Manager, Corp Communs Dept |
| Tsutomu Miura | General Manager, Ethical Products Marketing Dept |
| Yasuhiko Yamanaka | General Manager, Corp Strategy & Planning |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Kunio Takeda | Chairman & CEO |
| James L. Tyree | Board of Directors |
| Takshi Soda | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Takeda Pharmaceutical Company Limited | Chairman & CEO | Current |
| Takeda Pharmaceutical Company Limited | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Takeda Pharmaceutical Company Limited | President | Current |
| Organization | Position | Status |
|---|---|---|
| Takeda Pharmaceutical Company Limited | President, Consumer Healthcare | Current |
| Organization | Position | Status |
|---|---|---|
| Takeda Pharmaceutical Company Limited | President & COO | Current |
| Takeda Pharmaceutical Company Limited | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Takeda Pharmaceutical Company Limited | Managing Director | Current |
| Takeda Pharmaceutical Company Limited | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Takeda Pharmaceutical Company Limited | General Manager, Legal Dept | Current |
| Takeda Pharmaceutical Company Limited | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Takeda Pharmaceutical Company Limited | General Manager, Finance & Accounting Dept | Current |
| Organization | Position | Status |
|---|---|---|
| Takeda Pharmaceutical Company Limited | General Manager, Strategic Product Planning | Current |
| Organization | Position | Status |
|---|---|---|
| Takeda Pharmaceutical Company Limited | General Manager, Pharmaceutical Development Division | Current |
| Takeda Pharmaceutical Company Limited | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Takeda Pharmaceutical Company Limited | Managing Director & General Manager, Pharmaceutical Marketing Division | Current |
| Takeda Pharmaceutical Company Limited | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Takeda Pharmaceutical Company Limited | General Manager, Europe & Asia | Current |
| Organization | Position | Status |
|---|---|---|
| Takeda Pharmaceutical Company Limited | General Manager, Corp Communs Dept | Current |
| Takeda Pharmaceutical Company Limited | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Takeda Pharmaceutical Company Limited | General Manager, Ethical Products Marketing Dept | Current |
| Organization | Position | Status |
|---|---|---|
| Takeda Pharmaceutical Company Limited | General Manager, Corp Strategy & Planning | Current |
James Tyree is senior vice president, Pharmaceutical Operations Tyree first joined Abbott from 1978 until 1979 as a business analyst for a year. He rejoined the company in June 1997 and has been in various management positions including divisional vice president and general manager for Abbott's international division in Japan. He recently served as vice president, global licensing/new business development in the Pharmaceutical Products Division. He assumed his current role in 2006. Prior to re-joining Abbott in 1997, Tyree was president of Sugen Inc., a biotechnology start-up company and held various leadership positions at other pharmaceutical companies. He serves on the board of directors for TAP Pharmaceuticals, a joint venture between Abbott and Takeda Pharmaceutical Company Limited. He is a member of the advisory boards of the Polsky Center of Entrepreneurship at the University of Chicago and the Kellogg Center for Biotechnology at Northwestern University. He is a member of Richard M. Daley's Chicago Mayor's Council of Technology Advisors. Formerly chairman, he is also chairman of the board of directors of the Illinois Biotechnology Industry Organization. He earned bachelor's degrees in psychology and forensic studies and a master's degree in business administration from Indiana University.
| Organization | Position | Status |
|---|---|---|
| Northwestern University | Member | Current |
| University of Chicago | Member | Current |
| Kellogg Company | Member | Current |
| Takeda Pharmaceutical Company Limited | Board of Directors | Current |
| Indiana University | Master's Degree In Business Administration | Former |
| Organization | Position | Status |
|---|---|---|
| Takeda Pharmaceutical Company Limited | Board of Directors | Current |
Executive News
-
UPDATE 1-Japan's Takeda to buy IDM Pharma in cancer drug push
-
UPDATE 1-Japan's Takeda to buy IDM Pharma in cancer drug push
-
Takeda Posts 34% Profit Drop
Industry Transcripts by Seeking Alpha
-
Hansen Natural Corporation Q3 2009 Earnings Call Transcript
on Nov 06, 2009about HANS
-
Central European Distribution Corp. Q3 2009 Earnings Call Transcript
on Nov 06, 2009about CEDC
-
Red Robin Gourmet Burgers, Inc. F3Q09 (Qtr End 10/04/09) Earnings Call Transcript
on Nov 05, 2009about RRGB
-
Wendy’s/Arby’s Group Inc. Q3 2009 Earnings Call Transcript
on Nov 05, 2009about WEN
-
Starbucks Corp. F4Q09 (Qtr. End 09/27/09) Earnings Call Transcript
on Nov 05, 2009about SBUX
Glass Door
Takeda Pharmaceutical
IndustryTop Rated
